Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radezolid - Melinta Therapeutics

Next Previous
X
Search
Drug Profile

Radezolid - Melinta Therapeutics

Alternative Names: RX-01667; Rx-01_667; RX-103; RX-1741

Latest Information Update: 28 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rib-X Pharmaceuticals
  • Developer Melinta Therapeutics; Unknown
  • Class Antibacterials; Oxazolidinones; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Community-acquired pneumonia; Gram-positive infections; Skin and soft tissue infections
  • No development reported Acne vulgaris; Bacterial vaginosis

Most Recent Events

  • 28 Aug 2022 No recent reports of development identified for preclinical development in Bacterial-vaginosis in USA (Topical)
  • 14 Sep 2020 No development reported - Phase-II for Acne vulgaris (Topical)
  • 18 Jan 2018 Radezolid - Melinta Therapeutics receives Qualified Infectious Disease Product status for Bacterial vaginosis in USA before January 2018

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top